Literature DB >> 3718807

Stereoselective disposition of mexiletine in man.

O Grech-Belanger, J Turgeon, M Gilbert.   

Abstract

The pharmacokinetics of S-(+)- and R-(-)-mexiletine and of the corresponding conjugates were investigated in six healthy young volunteers after administration of a single 200 mg oral dose of racemic mexiletine hydrochloride. The values for the distribution rate constants as well as for the elimination half-lives of the two enantiomers were similar but the AUC of the S-(+)-enantiomer was always significantly higher (P less than 0.01) than that of the opposite enantiomer. The mean R/S ratios for unchanged mexiletine in serum and in urine were 0.78 +/- 0.12 (s.d.) and 0.80 +/- 0.21, respectively. Urinary excretion of mexiletine conjugates consisted mainly of the R-(-)-enantiomer; the mean R/S enantiomeric ratio over 48 h was 9.65 +/- 3.10. Serum concentrations of the conjugates were measured in three subjects. The mean R/S AUC ratio was 2.94 +/- 0.48 and the renal clearance of the R-(-)-enantiomer was significantly higher (P less than 0.02) than that of the S-(+)-enantiomer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3718807      PMCID: PMC1401041          DOI: 10.1111/j.1365-2125.1986.tb02829.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

1.  The distribution, metabolism and excretion of mexiletine in man.

Authors:  A H Beckett; E C Chidomere
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Absorption, distribution and elimination of mexiletine.

Authors:  L F Prescott; A Pottage; J A Clements
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

3.  Studies on the optical enantiomorphs of warfarin in man.

Authors:  R A O'Reilly
Journal:  Clin Pharmacol Ther       Date:  1974-08       Impact factor: 6.875

4.  Stereoselective sulfate conjugation of 4-hydroxypropranolol in vitro by different species.

Authors:  D D Christ; T Walle
Journal:  Drug Metab Dispos       Date:  1985 May-Jun       Impact factor: 3.922

5.  Mexiletine in normal volunteers.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-10       Impact factor: 4.335

6.  Plasma half-lives, plasma metabolites and anticoagulant efficacies of the enantiomers of warfarin in man.

Authors:  D S Hewick; J McEwen
Journal:  J Pharm Pharmacol       Date:  1973-06       Impact factor: 3.765

7.  The identification and analysis of mexiletine and its metabolic products in man.

Authors:  A H Beckett; E C Chidomere
Journal:  J Pharm Pharmacol       Date:  1977-05       Impact factor: 3.765

Review 8.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

9.  The clinical pharmacology of mexiletine.

Authors:  N P Campbell; J G Kelly; A A Adgey; R G Shanks
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

10.  Mexiletine (Kö 1173) in the management of ventricular dysrhythmias.

Authors:  N P Campbell; J G Kelly; R G Shanks; N C Chaturvedi; J E Strong; J F Pantridge
Journal:  Lancet       Date:  1973-08-25       Impact factor: 79.321

View more
  16 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 2.  Stereoselectivity in clinical pharmacokinetics and drug development.

Authors:  D B Campbell
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Apr-Jun       Impact factor: 2.441

Review 3.  New concepts affecting the use of antiarrhythmic agents.

Authors:  R L Woosley
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

Review 4.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

5.  Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

Authors:  A M Evans; R L Nation; L N Sansom; F Bochner; A A Somogyi
Journal:  Br J Clin Pharmacol       Date:  1988-12       Impact factor: 4.335

Review 6.  Clinical pharmacokinetics of mexiletine.

Authors:  L Labbé; J Turgeon
Journal:  Clin Pharmacokinet       Date:  1999-11       Impact factor: 6.447

Review 7.  Mexiletine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in the treatment of arrhythmias.

Authors:  J P Monk; R N Brogden
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

Review 8.  Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide.

Authors:  C P Denaro; N L Benowitz
Journal:  Med Toxicol Adverse Drug Exp       Date:  1989 Nov-Dec

9.  Stereoselective metabolism of mexiletine in Chagasic women with ventricular arrhythmias.

Authors:  V L Lanchote; E J Cesarino; V J Santos; A V Moraes Júnior; A M Zanardi; S R Santos
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 10.  Mexiletine. A review of its therapeutic use in painful diabetic neuropathy.

Authors:  B Jarvis; A J Coukell
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.